PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.18
Negative OCF/share while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would examine if a turnaround is realistic.
-0.31
Negative FCF/share while Drug Manufacturers - Specialty & Generic median is -0.03. Seth Klarman would question if the business is too capex-heavy.
-71.93%
Negative ratio while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would examine if negative OCF or unusual accounting drives this figure.
-9.34
Negative ratio while Drug Manufacturers - Specialty & Generic median is 0.44. Seth Klarman might see a severe mismatch of earnings and cash.
-36.53%
Negative ratio while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect deeper operational issues or near-zero revenue.